newsfilter
← Latest News
Business Wire·

Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Clinical update anticipated in mid-2026 for Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001) with at least 20 lupus nephritis (LN) and systemic lupus erythematosus (SLE) patients